Four new drugs now in development could change the way diabetes is treated. Novo Nordisk’s oral GLP-1 Semaglutide could offer an easier-to-take option and help delay the need for direct insulin treatment. Opko’s Oxyntomodulin (OPK-88003) is a leader in a new class of dual GLP-1 and glucagon receptor agonist drugs. Oramed just started a Phase 2 trial on an oral insulin drug, and ITCA 650 is a unique subdermal implant GLP-1 inhibitor that is inserted once every 6 months. Read more